Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Updated Analysis of the Observational Giotag Study
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8–46.3) overall and 45.7 months (90% CI: 45.3–51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8–30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT03370770
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The clinical effectiveness of afatinib has been confirmed by recent results of real-world studies.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [99]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a global, noninterventional study of patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib in a real-world setting, which showed median time to treatment failure of 28.1 months (90% CI, 26.8–30.3) and median OS of 41.3 months (90% CI, 36.8–46.3).”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [99]
The cited source says what the claim attributes to it.
In the citing paper
“some data show that a sequential treatment strategy consisting of afatinib followed by osimertinib can provide a viable, long-term treatment option for patients who develop T790M-mediated resistance”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574
Self-citationWu, Y.-L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Tsuji, F., Linke, R., Rosell, R., Corral, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30608-3 · Cited by 1,216
Park, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30033-x · Cited by 1,183
Self-citationReck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 946
Oxnard, G. R., Hu, Y., Mileham, K. F., Husain, H., Costa, D. B., Tracy, P., Feeney, N., Sholl, L. M., Dahlberg, S. E., Redig, A. J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2969 · Cited by 686
Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574
Yang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3223 · Cited by 571
Self-citation
Cited by
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Pottier, C., Fresnais, M., Gilon, M., Jérusalem, G., Longuespée, R., & Sounni, N. E. (2020) · Cancers · doi:10.3390/cancers12030731 · Cited by 515
“2 months), with a favorable tolerability profile [20,23,24].”
BackgroundShah, R., & Lester, J. F. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.12.003 · Cited by 174
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220931926 · Cited by 115
“The clinical effectiveness of afatinib has been confirmed by recent results of real-world studies.(89,99) In addition, afatinib-related AEs are manageable by means of tolerability-guided dose adjustments, along with the use of AE-specific treatment administered either prophylactically or as needed.”
BackgroundResultNazha, B., Yang, J. C., & Owonikoko, T. K. (2020) · Future Oncology · doi:10.2217/fon-2020-0951 · Cited by 84
Self-citationHochmair, M. J., Morabito, A., Hao, D., Yang, C., Soo, R. A., Yang, J. C., Gucalp, R. A., Halmos, B., Märten, A., & Čufer, T. (2020) · Future Oncology · doi:10.2217/fon-2020-0740 · Cited by 70
Self-citationOverall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations
Hayashi, H., Nadal, E., Gray, J. E., Ardizzoni, A., Caria, N., Puri, T., & Grohé, C. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.10.009 · Cited by 68
Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
Bian, D., Sun, L., Hu, J., Duan, L., Xia, H., Zhu, X., Sun, F., Zhang, L., Yu, H., Xiong, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40349-z · Cited by 60
“The GioTag study demonstrated superior OS in NSCLCm+ who received sequential Afatinib-to-Osimertinib treatment 43,44 .”
Self-citationTherapeutic Sequencing in ALK+ NSCLC
Elsayed, M., & Christopoulos, P. (2021) · Pharmaceuticals · doi:10.3390/ph14020080 · Cited by 54
“the sequence afatinib-osimertinib [11,18]; and second, the”
BackgroundLi, W., & Cui, J. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03296-6 · Cited by 53
Ito, K., Morise, M., Wakuda, K., Hataji, O., Shimokawaji, T., Takahashi, K., Furuya, N., Takeyama, Y., Gotô, Y., Abe, T., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100115 · Cited by 51
“3 months.(11,12) In addition, this study showed that the Asian population had prolonged PFS compared with the non-Asian population.”
ResultPretelli, G., Spagnolo, C. C., Ciappina, G., Santarpía, M., & Pasello, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108878 · Cited by 43
Kim, E. S., Melosky, B. L., Park, K., Yamamoto, N., & Yang, J. C. (2021) · Future Oncology · doi:10.2217/fon-2021-0195 · Cited by 42
Self-citationChua, K. P., Teng, Y. H. F., Tan, A. C., Takano, A. M., Alvarez, J. J. S., Nahar, R. R., Rohatgi, N., Lai, G. G. Y., Aung, Z. W., Yeong, J. P.-S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4607 · Cited by 42
“with afatinib followed by osimertinib may result in improved outcomes in a significant proportion of patients (11, 12).”
BackgroundSelf-citationProvencio, M., Serna‐Blasco, R., Franco, F., Calvo, V., Royuela, A., Auglytė, M., Sánchez-Hernández, A., Campayo, M. D. J., Girón, C. G., Dómine, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.031 · Cited by 36
Girard, N. (2019) · Future Oncology · doi:10.2217/fon-2019-0400 · Cited by 32
Melosky, B. L., Banerji, S. O., Blais, N., Chu, Q. S.-C., Juergens, R. A., Leighl, N. B., Liu, G., & Cheema, P. K. (2020) · Current Oncology · doi:10.3747/co.27.6007 · Cited by 31
Wu, S., Yu, C., Yang, J. C., & Shih, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920946156 · Cited by 34
Self-citationde Marinis, F., Лактионов, К. К., Poltoratskiy, A., Egorova, I. V., Hochmair, M. J., Passaro, A., Migliorino, M. R., Metro, G., Gottfried, M., Tsoi, D. T. F., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.12.011 · Cited by 29
“Key real-world studies of afatinib treatment for EGFRm + NSCLC are summarized in a recent review by Park and Yang [26] and include: the observational RealGiDo study [29] which reported that dose adjustment of afatinib did not affect efficacy and the GioTag study [30,31] which reported that sequential afatinib and osim…”
Self-citationBergonzini, C., Leonetti, A., Tiseo, M., Giovannetti, E., & Peters, G. J. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1746269 · Cited by 29
Kitadai, R., & Okuma, Y. (2022) · Cancers · doi:10.3390/cancers14102519 · Cited by 28
Lü, S., Shih, J., Jang, T. W., Liam, C. K., & Yu, Y. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01696-9 · Cited by 26
Saw, S. P. L., Le, X., Hendriks, L. E. L., & Remón, J. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432516 · Cited by 25
Buder, A., Hochmair, M. J., & Filipits, M. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00781-3 · Cited by 24
“second-generation EGFR TKI followed by osimertinib is still a valid chemotherapy-free regimen that could be offered to patients [1, 2].”
BackgroundSelf-citationChen, Y., Tsai, M., Lee, M., Kuo, C., Shen, M., Tsai, Y., Chen, H., Hung, J., Huang, M., Chong, I., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08235-3 · Cited by 23
“6 months in patients with an exon 19 deletion [30].”
BackgroundSelf-citationHsieh, P., Wu, Y., Huang, C.-Y., Yang, M.-C., Kuo, C., Tzeng, I., & Lan, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.869390 · Cited by 21
Kobayashi, N., Katakura, S., Kamimaki, C., Somekawa, K., Fukuda, N., Tanaka, K., Watanabe, K., Horita, N., Hara, Y., Piao, H., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13878 · Cited by 19
Hsu, P., Huang, C.-Y., Wang, C., Kuo, C. S., Chu, C., Tung, P., Huang, A. C., Wang, C., Chiu, L., Fang, Y., et al. (2020) · Pharmaceuticals · doi:10.3390/ph13110331 · Cited by 18
“The EGFR T790M mutation (methionine-to-threonine substitution at amino acid position 790 in exon 20) is the most frequently acquired point mutation (30–60%), leading to resistance to afatinib in NSCLC [32,33].”
BackgroundSelf-citationHirsh, V., & Singh, J. R. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa197 · Cited by 17
“7 months for patients with Del19-positive tumors.(70)”
BackgroundSequential treatment in advanced non–small cell lung cancer harboring EGFR mutations
Hsu, P., Chang, J. W., Chang, C., Huang, C., Yang, C., Kuo, C. S., Fang, Y., & Wu, C. (2022) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666221132731 · Cited by 17
Self-citationMatsumoto, Y., Sawa, K., Fukui, M., Oyanagi, J., Yoshimoto, N., Suzumura, T., Watanabe, T., Kaneda, H., Mitsuoka, S., Asai, K., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.029 · Cited by 16
Kim, T., Jang, T. W., Choi, C., Kim, M., Lee, S. Y., Park, C., Chang, Y. S., Lee, K. Y., Kim, S. J., Yang, S. H., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4127 · Cited by 16
Uehara, Y., Takeyasu, Y., Yoshida, T., Tateishi, A., Torasawa, M., Hosomi, Y., Masuda, K., Shinno, Y., Matsumoto, Y., Okuma, Y., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100058 · Cited by 16
Lee, C., Ahmed, I., Miao, E., Chung, S., Patel, K., Kohn, N. E., & Seetharamu, N. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211020798 · Cited by 16
“6months and a 2-year survival of 80% showing this sequential treatment to be a promising strategy.(23,24) With TKIs such as erlotinib becoming available in generic form, studies evaluating optimal sequencing of TKIs both with regards to efficacy and costeffectiveness may need to be re-visited.”
BackgroundMaso, A. D., Lorenzi, M., Ferro, A., Pilotto, S., Cecere, F. L., Follador, A., Polo, V., Conte, A. D., Sartori, G., Giavarra, M., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0356 · Cited by 16
Narayanan, J., Tamilanban, T., Senthilkumar, P., Guru, A., Saravanan, M., Kathiravan, M. K., & Arockiaraj, J. (2023) · Archives of Microbiology · doi:10.1007/s00203-023-03559-z · Cited by 15
MITSUYA, S., Tsuruoka, K., Kanaoka, K., Funamoto, T., Tsuji, H., Matsunaga, N., Nakamura, T., Tamura, Y., Imanishi, M., IKEDA, S., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15331 · Cited by 14
Kudo, K., Nishii, K., Makimoto, G., Ishikawa, N., Tsubata, Y., Kodani, M., Fujimoto, N., Yamasaki, M., Kubota, T., Takigawa, N., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03893-z · Cited by 14
Wu, C., Chang, C., Huang, C., Yang, C., Kuo, C. S., Hsu, P., & Chang, J. W. C. (2022) · Cancers · doi:10.3390/cancers14030674 · Cited by 13
“Although osimertinib demonstrated excellent survival outcomes contrasted with standard treatments (erlotinib or gefitinib) when used as a frontline treatment [12,13], first- and second-generation TKIs remain widely used in daily practice because sequential TKI treatment may benefit patients who develop T790M mutation,…”
BackgroundSelf-citationTreatment Sequencing in Oncology: Balancing Clinical Trial and Real-World Evidence
Caffo, O. (2019) · Future Oncology · doi:10.2217/fon-2019-0415 · Cited by 13
Ito, K., Murotani, K., Kubo, A., Kunii, E., Taniguchi, H., Shindoh, J., Asada, K., Imaizumi, K., Takahashi, K., Karayama, M., et al. (2020) · Cancer Science · doi:10.1111/cas.14560 · Cited by 13
Gilardone, S., Thapa, R., Laborde, J., Shafique, M. R., Saltos, A. N., Creelan, B., Tanvetyanon, T., Chiappori, A., Simon, G. R., Haura, E. B., et al. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-686 · Cited by 12
“The authors of this study noted that time to treatment failure with second-line osimertinib did not appear to be impacted by prior afatinib therapy (12).”
Park, K., Kim, J.-S., Kim, J.-H., Kim, Y., Kim, H., Cho, E. K., Jin, J., Kim, M., Märten, A., & Kang, J. (2021) · BMC Cancer · doi:10.1186/s12885-021-08445-9 · Cited by 12
Self-citationKatayama, Y., Yamada, T., Tokuda, S., Okura, N., Nishioka, N., Morimoto, K., Tanimura, K., Morimoto, Y., Iwasaku, M., Horinaka, M., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4504 · Cited by 11
Yamamoto, N., Mera, T., Märten, A., & Hochmair, M. J. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01187-y · Cited by 11
Self-citationWang, W., Liu, H., Wen, Y., Zhang, Y., & Ma, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1619517 · Cited by 9
Jung, H. A., Park, S., Sun, J., Lee, S., Ahn, J. S., Ahn, M., & Park, K. (2020) · Biology · doi:10.3390/biology9100326 · Cited by 9
Nilsson, F. O. L., Gál, P., Houisse, I., Ivanova, J. I., & Asanin, S. T. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1901722 · Cited by 9
Absence of copy number gain ofEGFR: A possible predictive marker of long‐term response to afatinib
Nakamura, T., Sato, A., Nakashima, C., Abe, T., Iwanaga, K., Umeguchi, H., Kawaguchi, A., & Sueoka‐Aragane, N. (2022) · Cancer Science · doi:10.1111/cas.15655 · Cited by 9
Feinberg, B. A., Halmos, B., Gucalp, R. A., Tang, W., Moehring, B., & Hochmair, M. (2020) · Future Oncology · doi:10.2217/fon-2020-0188 · Cited by 8
Self-citationSoo, R. A., Seto, T., Gray, J. E., Thiel, E., Taylor, A., Sawyer, W., Karimi, P., Marchlewicz, E. H., & Brouillette, M. A. (2021) · Drugs - Real World Outcomes · doi:10.1007/s40801-021-00272-5 · Cited by 8
Self-citationGirard, N., Moro‐Sibilot, D., Bouée, S., Emery, C., Torreton, E., Lay, K. L., Luciani, L., Maritaz, C., & CHOUAID, C. (2020) · Future Oncology · doi:10.2217/fon-2020-0084 · Cited by 8
Ju, L., Dong, Z., Yang, J., & Li, M. (2020) · Oncology Letters · doi:10.3892/ol.2020.12218 · Cited by 6
“However, the median overall survival (OS) time of the patients with NSCLC treated with pembroli‑ zumab alone is only 20 months (5), which is poor compared with targeted therapy in adenocarcinomas (6).”
Self-citationLiu, R., Zhou, J., & Ling, X. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221103215 · Cited by 6
Nishimura, T., Okano, T., Naito, M., Iwanaka, S., Ohiwa, A., Sakakura, Y., Yasuma, T., Fujimoto, H., D’Alessandro‐Gabazza, C. N., Oomoto, Y., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13870 · Cited by 6
“However, real-world data showed that the median OS (9 months) of patients with ECOG PS ≥2 patients treated with osimertinib as secondline therapy was shorter than patients with ECOG PS 0 or 1.(28) Clinical trials are currently underway to assess the efficacy of novel molecular-targeted drugs or immune checkpoint inhib…”
MethodBrueckl, W. M., Reck, M., Schäfer, H., Neben, K., Griesinger, F., Rawluk, J. K., Krüger, S., Kokowski, K., Ficker, J. H., Möller, M., et al. (2022) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2022.10.009 · Cited by 7
Tu, H., & Wu, Y.-L. L. C. (2020) · Future Oncology · doi:10.2217/fon-2020-0320 · Cited by 6
Naka, G., Yokoyama, T., Usui, K., Ishida, H., Kishi, K., Uemura, K., Ohashi, Y., & Kunitoh, H. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac032 · Cited by 5
“These may have affected the response rate and PFS; (iii) PFS also includes a guarantee-time bias/lead-time bias and thus cannot simply be compared with the results of AURA3 or other studies of EGFR-TKIs; (iv) currently, osimertinib is recommended as first-line therapy (12), but other treatment strategies such as ramuc…”
Cheng, W., Shen, Y., Chen, C., Liao, W.-C., Chen, H.-J., Hsia, T., Chen, C., & Tu, C. (2022) · Diagnostics · doi:10.3390/diagnostics13010129 · Cited by 5
“Sequential afatinib and osimertinib provide good outcomes in real-world clinical practice, especially in Asian patients [8,9].”
BackgroundYoshioka, H., Kato, T., Okamoto, I., Tanaka, H., Hida, T., Seto, T., Kiura, K., Tian, Y., Azuma, H., & Yamamoto, N. (2020) · Future Oncology · doi:10.2217/fon-2019-0659 · Cited by 5
Cortellini, A., Ficorella, C., Crisci, R., & Divisi, D. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1733 · Cited by 5
“7 months for patients with exon 19 deletion (7).”
BackgroundKwok, W. C., Ho, J., Tam, T. C. C., Ip, M., & Lam, D. C. L. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14528 · Cited by 4
Hsu, P., Huang, C.-Y., Lin, Y., Lee, S.-H., Chiu, L., Wu, C., Kuo, C. S., Ju, J., Huang, A. C., Ko, H., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1249106 · Cited by 3
Self-citationJoshi, J. S., Pandit, A., Tarapara, B. V., Patel, H. V., Bhavnagari, H. M., Panchal, H. P., & Shah, F. D. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08432-2 · Cited by 2
Rational approach to the treatment of EGFR-positive lung cancer
Реутова, Е. В., Лактионов, К. К., Yudin, D. I., & Сергеевич, А. М. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-19-51-56 · Cited by 2
Alrashidi, N. (2020) · Indian Journal of Surgery · doi:10.1007/s12262-020-02141-x · Cited by 1
Ying, H., Chen, Y., Lin, W., Fan, Y., Chen, M., & Jin, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-20263-8 · Cited by 1
Illini, O. (2025) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-025-01087-8 · Cited by 1
“Conversely, FLAURA2 showed higher rates of myelosuppression and gastrointestinal toxicity, making it less suitable for patients with hematologic frailty or poor chemotherapy tolerance [5].”
Tu, H., Li, Y.-S., Yang, J., Chen, H., Jiang, B., Zhong, W., Yang, X., & Wu, Y.-L. L. C. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01025-6 · Cited by 1
“Consistent with that study, our findings provide further support for the sequential use of afatinib followed by osimertinib, particularly in Del19-positive NSCLC [34, 35].”
ResultSelf-citationTreating EGFR-positive advanced cancer lung – Did the water just get muddier?
Sahoo, T. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_76_19 · Cited by 1
Андреевна, К. А., & Феденко, А. А. (2020) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2020-19-6-119-125 · Cited by 1
“При медиане наблюдения 30,3 мес медиана общей выживаемости во всей популяции больных составила 41,3 мес (90 % ДИ: 36,8–46,3) и 45,7 мес (90 % ДИ: 45,3–51,5) у пациентов с делецией в 19 экзоне EGFR [40, 41].”
Liu, X., Fu, M., Jia, C., Wang, X., Song, Y., & Peng, C. (2022) · PubMed Central · Cited by 1
Ma, W., Sheng, Z., Niu, Y., Yan, B., Chen, Y., Yang, H., & Li, R. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20955 · Cited by 1
Systemic treatment of EGFR-mutated non-small cell lung cancer
Czyżykowski, R. Ł., Wrona, E., Tałajko, A., Hasińska, A. M., & Potemski, P. J. (2025) · Oncology in Clinical Practice · doi:10.5603/ocp.100697 · Cited by 1
Kim, T., Jang, T. W., Choi, C., Kim, M., Lee, S. Y., Park, C., Chang, Y. S., Lee, K. Y., Kim, S. J., Yang, S. H., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-215079/v1 · Cited by 1
Possibilities of consistent targeted therapy for EGFR-positive NSCLC. Clinical case
Kozlov, V. V., & Gulyaeva, L. F. (2019) · P A Herzen Journal of Oncology · doi:10.17116/onkolog20198041289
Welcome to the 16th Volume of Future Oncology
Jenkins, R., & Gautier, L. J. (2019) · Future Oncology · doi:10.2217/fon-2019-0741
Moiseenko, F. V., Bogdanov, A. A., Volkov, N., Zhabina, A. S., & Fedyanin, M. Y. (2020) · Malignant tumours · doi:10.18027/2224-5057-2020-10-2-1
Past, Present and Future Oncology: Welcome to Volume 17
Gautier, L. J. (2021) · Future Oncology · doi:10.2217/fon-2020-1200
Estevinho, F., Silva, A. C., Cirnes, L., & Amaro, T. (2021) · Revista do Grupo de Estudos do Cancro do Pulmão · doi:10.32932/gecp.2021.07.015
Ju, L., Dong, Z., Yang, J., Li, J., & Ren, R.-Z. (2019) · doi:10.21203/rs.2.17492/v1
“In the era of immunotherapy, Pembrolizumab was listed as the firstline treatment for NSCLC patients with PD-L1 > 50% by 2019 NCCN guideline, but the median Overall Survival (OS) is only 20 months treated with Pembrolizumab alone [2], which is very limited compared with the targeted therapy in adenocarcinomas as we kno…”
BackgroundSelf-citationNutzen der Labormedizin in der Schweiz
Schlander, M., Schäfer, R., & Selberg, L. (2023) · Springer eBooks · doi:10.1007/978-3-662-66825-2
Schlander, M., Schäfer, R., & Selberg, L. (2023) · Springer eBooks · doi:10.1007/978-3-662-66825-2_4
Batra, U., Sharma, M., Jain, P., Narayan, S., Jain, A., Soni, S., & Nathany, S. (2024) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_893_20
Epidermal growth factor receptor blockers – known possibilities and new perspectives in oncology
Frantsiyants, E. M., Kaplieva, I. V., Shalashnaya, E. V., Shikhlyarova, A. I., Александровна, М. Н., Dimitriadi, S. N., Алексеев, Э. К., Kachesova, P. S., Trepitaki, L. K., & Александровна, А. К. (2025) · Research and Practical Medicine Journal · doi:10.17709/2410-1893-2025-12-4-8
“По сравнению с первым поколением EGFR-ТКИ, осимертиниб способствует увеличению медианы выживаемости без прогрес-сирования – 10,2 мес. против 8,9 мес., и имеет бла-гоприятный профиль переносимости [18].”
Kim, Y.-J. (2021) · UWSpace (University of Waterloo)
Evolución del manejo del cáncer de pulmón
Cervantes, J. M. (2025) · Oncología (Ecuador) · doi:10.33821/809
Tan, A. C., Kim, T. J., Zhou, S., Lim, Y. N., Ho, G. F., Tho, L. M., Baisamut, T. R., Prasongsook, N., Lee, S., Tan, S. H., et al. (2026) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2026.101027
“11 This study also reinforces the importance of resistance profiling, particularly when considering both tissue and plasma sampling, to guide second-line treatment decisions.”
Metadata
- Authors
- Hochmair, M. J., Morabito, A., Hao, D., Yang, C.-T., Soo, R. A., Yang, J. C.-H., Gucalp, R., Halmos, B., Wang, L., Märten, A., & Cufer, T.
- Affiliations
- Ludwig Boltzmann Institute for Lung Health (AT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Tom Baker Cancer Center, Cummings School of Medicine, University of Calgary, Calgary, Alberta, Canada
- Chang Gung Memorial Hospital (TW)
- National University Hospital (SG)
- National Taiwan University Hospital (TW)
- Albert Einstein College of Medicine (US)
- Department of Oncology, Montefiore/Albert Einstein Cancer Center, Bronx, NY, USA
- Boehringer Ingelheim (Taiwan) (TW)
- Boehringer Ingelheim (Germany) (DE)
- University Clinic Golnik, University of Ljubljana, Ljubljana, Slovenia
- ORCID
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2019-08-02
- Volume
- 15
- Issue
- 25
- Pages
- 2905-2914
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- OpenAlex
- W2965410028
- Cited by
- 85
- References
- 27
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 8 · 2022: 13 · 2021: 21 · 2020: 23 · 2019: 10
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Future Oncology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DiRROS repository (University of Maribor) (publishedVersion, cc-by-nc-nd)
- Funders
- Boehringer Ingelheim
- AstraZeneca
- Pfizer
- Novartis
- Takeda
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- afatinib, osimertinib, EGFR-mutant non-small cell lung cancer, T790M, time to treatment failure, overall survival, EGFR exon 19 deletion, L858R mutation, real-world evidence
- MeSH terms
- Afatinib, Acrylamides, Aniline Compounds, Carcinoma, Non-Small-Cell Lung, Humans, Indoles, Mutation, Pyrimidines, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.